Alvotech

Setting a new standard for biosimilars

Alvotech is working to bring more affordable and accessible biologic medicines to patients around the world. From development through manufacturing, Alvotech is fully integrated and fully focused on biosimilars.

www.alvotech.com

Investment year

2013

Status

Active

Sector

Biotech

Alvotech News

All categories

April 12, 2023Investment newsAlvotech

Mitsui Acquires Convertible Bonds Issued by Alvotech and Forges Strategic Healthcare Collaboration Agreement with Aztiq

February 9, 2023Company newsAlvotech

EMA Confirms Acceptance of Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)

January 25, 2023Company newsAlvotech

Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) as Simlandi in Saudi Arabia

January 23, 2023Company newsAlvotech

Alvotech Completes $137 Million Private Share Placement

January 13, 2023Company newsAlvotech

Alvotech and Fuji Pharma Expand Partnership Adding a New Biosimilar Candidate

January 11, 2023Company newsAlvotech

Alvotech Initiates Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®

January 6, 2023Company newsAlvotech

Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)

December 22, 2022Company newsAlvotech

Update on U.S. Regulatory Status of AVT02, Alvotech’s Proposed High-Concentration, Interchangeable Biosimilar to Humira®

December 16, 2022Company newsAlvotech

Alvotech Completes $70 Million Private Placement

December 8, 2022Company newsAlvotech

Alvotech Shares Start Trading on Nasdaq Iceland Main Market

December 7, 2022Company newsAlvotech

Alvotech and STADA Broaden Access to Hukyndra® adalimumab biosimilar in Europe

Róbert Wessman Aztiq Founder and Chairman

December 2, 2022Company newsAlvotech

Alvotech Announces Changes to its Leadership Team

December 1, 2022Company newsAlvotech

Alvotech Announces Changes to its Leadership Team

November 16, 2022Company newsAlvotech

Alvotech secures financing facilities of approximately $136 Million

November 15, 2022Company newsAlvotech

Alvotech Announces Australian Marketing Authorization for AVT02, a Biosimilar to Humira®

October 19, 2022Company newsAlvotech

Alvotech and JAMP Pharma Expand Exclusive Partnership Adding Two Biosimilar Candidates for Canadian Market, Bringing New Options for Patients in Specialty Care

October 17, 2022Company newsAlvotech

Alvotech’s Partner Submits Application for Marketing Approval of First Biosimilar Candidate in Japan

October 12, 2022Company newsAlvotech

Alvotech Appoints Sarah Tanksley as Chief Quality Officer

September 2, 2022Company newsAlvotech

Alvotech Reports First Half 2022 Financial Results

August 29, 2022Company newsAlvotech

Alvotech Announces Corporate Sustainability Participation and Discloses ESG Data